KTLA

Core One Labs' GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of Psychedelic Prodrugs with Long-established Compounding Pharmacy

VANCOUVER, BC / ACCESSWIRE / May 1, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly-owned subsidiaries ...
Wane

Core One Labs' Akome Signs Contract with University of Barcelona: Initiating Animal Model Studies on Psychedelics Drug Development to Combat a Variety of Neurological Diseases

VANCOUVER, BC / ACCESSWIRE / January 24, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN: A3CSSU) (the "Company" or "Core One"), in follow-up to its press release dated September ...

New psychedelic candidate may spare the gut while still healing the brain

Psychedelic drugs are best known for altering perception and producing vivid hallucinations, but scientists are increasingly ...
The Atlantic

Psychedelics Are Challenging the Scientific Gold Standard

Tomorrow, a Food and Drug Administration advisory committee will meet to discuss whether the United States should approve its first psychedelic drug. The fate of the treatment—MDMA-assisted therapy ...
Science Daily

New method tracks how psychedelics affect neurons in minutes

A new tool to track the neurons and molecules activated in the brain by psychedlic drugs could help scientists unlock the benefits of psychedelic treatments for patients with brain disorders.

Psychedelics amplify brain connectivity through serotonin receptors, study suggests

LSD, DMT and mescaline profoundly alter how we perceive, feel and think. After decades of neglect, they are again the subject ...